BioCentury | Feb 24, 2014
Finance

Microcap M&A

...enough value to attract investors and improve its access to capital. Mast began life as Adventrx Pharmaceuticals Inc....
BioCentury | Mar 25, 2013
Clinical News

ANX-514: Development discontinued

...Mast Therapeutics (formerly Adventrx Pharmaceuticals Inc. ) discontinued development of ANX-514 last year to focus on MST-188...
...discontinued development of ANX-514 last year to focus on MST-188 . In October 2011, Adventrx...
...trial (see BioCentury, May 18, 2009). Shin Poong has South Korean rights to ANX-514 from Adventrx...
BioCentury | Feb 18, 2013
Clinical News

Purified poloxamer 188: QT/QTc study started

...The compound has Fast Track and Orphan Drug designation in the U.S. for the indication. Adventrx Pharmaceuticals Inc....
BioCentury | Feb 11, 2013
Clinical News

Purified poloxamer 188: Phase III started

...The compound has Fast Track and Orphan Drug designation in the U.S. for the indication. Adventrx Pharmaceuticals Inc....
BioCentury | Jan 14, 2013
Company News

Adventrx management update

Adventrx Pharmaceuticals Inc. (NYSE-M:ANX), San Diego, Calif. Business: Cancer, Infectious, Hematology Transitioned: Brandi Roberts to CFO and SVP from VP of finance WIR Staff cancer Hematology Infectious...
BioCentury | Nov 5, 2012
Clinical News

ANX-188: Phase III start

...This quarter, Adventrx will begin a double-blind, placebo-controlled Phase III trial evaluating ANX-188 in 388 patients...
...cell disease ages 8-17 years and who are experiencing acute pain typical of vaso-occlusive crisis. Adventrx Pharmaceuticals Inc....
BioCentury | Aug 20, 2012
Company News

Adventrx management update

Adventrx Pharmaceuticals Inc. (NYSE-M:ANX), San Diego, Calif. Business: Cancer, Infectious, Hematology Hired: Santosh Vetticaden as CMO and SVP, formerly SVP and chief medical and development officer of Cubist Pharmaceuticals Inc. WIR Staff cancer Hematology Infectious...
BioCentury | Mar 19, 2012
Financial News

Adventrx financial update

...of its securities. The company, which closed Friday at $0.64, has 47.7 million shares outstanding. Adventrx Pharmaceuticals Inc....
BioCentury | Jan 2, 2012
Finance

Living creatively

...NASDAQ:PCRX) 11/16/11 $52.3 $164.3 $218.7 33% Idenix Pharmaceuticals Inc. (NASDAQ:IDIX) 11/16/11 $61.1 $686.1 $786.3 15% Adventrx Pharmaceuticals Inc....
BioCentury | Nov 14, 2011
Finance

Highlights of weekly biotech stock moves

...to $7.74 for the week (see B22) . Ebb & Flow Cancer and hematology company Adventrx...
Items per page:
1 - 10 of 166
BioCentury | Feb 24, 2014
Finance

Microcap M&A

...enough value to attract investors and improve its access to capital. Mast began life as Adventrx Pharmaceuticals Inc....
BioCentury | Mar 25, 2013
Clinical News

ANX-514: Development discontinued

...Mast Therapeutics (formerly Adventrx Pharmaceuticals Inc. ) discontinued development of ANX-514 last year to focus on MST-188...
...discontinued development of ANX-514 last year to focus on MST-188 . In October 2011, Adventrx...
...trial (see BioCentury, May 18, 2009). Shin Poong has South Korean rights to ANX-514 from Adventrx...
BioCentury | Feb 18, 2013
Clinical News

Purified poloxamer 188: QT/QTc study started

...The compound has Fast Track and Orphan Drug designation in the U.S. for the indication. Adventrx Pharmaceuticals Inc....
BioCentury | Feb 11, 2013
Clinical News

Purified poloxamer 188: Phase III started

...The compound has Fast Track and Orphan Drug designation in the U.S. for the indication. Adventrx Pharmaceuticals Inc....
BioCentury | Jan 14, 2013
Company News

Adventrx management update

Adventrx Pharmaceuticals Inc. (NYSE-M:ANX), San Diego, Calif. Business: Cancer, Infectious, Hematology Transitioned: Brandi Roberts to CFO and SVP from VP of finance WIR Staff cancer Hematology Infectious...
BioCentury | Nov 5, 2012
Clinical News

ANX-188: Phase III start

...This quarter, Adventrx will begin a double-blind, placebo-controlled Phase III trial evaluating ANX-188 in 388 patients...
...cell disease ages 8-17 years and who are experiencing acute pain typical of vaso-occlusive crisis. Adventrx Pharmaceuticals Inc....
BioCentury | Aug 20, 2012
Company News

Adventrx management update

Adventrx Pharmaceuticals Inc. (NYSE-M:ANX), San Diego, Calif. Business: Cancer, Infectious, Hematology Hired: Santosh Vetticaden as CMO and SVP, formerly SVP and chief medical and development officer of Cubist Pharmaceuticals Inc. WIR Staff cancer Hematology Infectious...
BioCentury | Mar 19, 2012
Financial News

Adventrx financial update

...of its securities. The company, which closed Friday at $0.64, has 47.7 million shares outstanding. Adventrx Pharmaceuticals Inc....
BioCentury | Jan 2, 2012
Finance

Living creatively

...NASDAQ:PCRX) 11/16/11 $52.3 $164.3 $218.7 33% Idenix Pharmaceuticals Inc. (NASDAQ:IDIX) 11/16/11 $61.1 $686.1 $786.3 15% Adventrx Pharmaceuticals Inc....
BioCentury | Nov 14, 2011
Finance

Highlights of weekly biotech stock moves

...to $7.74 for the week (see B22) . Ebb & Flow Cancer and hematology company Adventrx...
Items per page:
1 - 10 of 166